Deciphera Pharmaceuticals Inc.
| NASDAQ: DCPH | Healthcare / Biotechnology / USA |
| 47.00 | -0.2300 | -0.49% | Vol 411.12K | 1Y Perf 8.48% |
| Apr 16th, 2021 16:00 DELAYED |
| BID | 47.00 | ASK | 47.02 | ||
| Open | 47.40 | Previous Close | 47.23 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 73.71 | Analyst Rating | Strong Buy 1.40 | |
| Potential % | 56.83 | Finscreener Ranking | ★★★★+ 57.00 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★+ 54.61 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★+ 63.59 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Market Cap | 2.71B | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 26.16 | Earnings Date | 4th May 2021 |
Today's Price Range 45.0247.54 | 52W Range 39.4268.40 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 7.28% | ||
| 1 Month | 6.92% | ||
| 3 Months | -6.13% | ||
| 6 Months | -20.22% | ||
| 1 Year | 8.48% | ||
| 3 Years | 97.65% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -58.98 | |||
ROE last 12 Months | -46.81 | |||
ROA (5Y Avg) | -20.10 | |||
ROA last 12 Months | -40.37 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -46.13 | |||
Return on invested Capital Q | -10.72 | |||
Return on invested Capital Y | -47.62 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 6.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -9.30 | ||||
| 4.71 | ||||
| 60.40 | ||||
| - | ||||
| -15.60 | ||||
| -4.30 | ||||
| 4.71 | ||||
| 9.43 | ||||
| 2.04B | ||||
| Forward PE | -16.65 | |||
| PEG | -0.44 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.10 | ||||
| 8.30 | ||||
| 0.05 | ||||
| 0.06 | ||||
| -22 579.40 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 99.50 | ||||
| -1 198.90 | ||||
| -1 189.80 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 42.03M | ||||
| 0.73 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -1.16 | -1.10 | 5.17 |
| Q03 2020 | -1.32 | -1.13 | 14.39 |
| Q02 2020 | -1.34 | -1.20 | 10.45 |
| Q01 2020 | -1.28 | -1.36 | -6.25 |
| Q04 2019 | -1.13 | -1.31 | -15.93 |
| Q03 2019 | -1.19 | -1.28 | -7.56 |
| Q02 2019 | -1.06 | -0.56 | 47.17 |
| Q01 2019 | -0.79 | -1.25 | -58.23 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -1.09 | 6.03 | Positive |
| 6/2021 QR | -0.96 | 15.79 | Positive |
| 12/2021 FY | -4.27 | 3.17 | Positive |
| 12/2022 FY | -2.63 | 10.24 | Positive |
| Next Report Date | 4th May 2021 |
| Estimated EPS Next Report | -1.09 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | 21.00 |
| Volume Overview | |
|---|---|
| Volume | 411.12K |
| Shares Outstanding | 57.63M |
| Trades Count | 6.23K |
| Dollar Volume | 19.33M |
| Avg. Volume | 434.10K |
| Avg. Weekly Volume | 322.21K |
| Avg. Monthly Volume | 362.72K |
| Avg. Quarterly Volume | 443.64K |
Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) stock closed at 47 per share at the end of the most recent trading day (a -0.49% change compared to the prior day closing price) with a volume of 414.52K shares and market capitalization of 2.71B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 350 people. Deciphera Pharmaceuticals Inc. CEO is Steven L. Hoerter.
The one-year performance of Deciphera Pharmaceuticals Inc. stock is 8.48%, while year-to-date (YTD) performance is -17.64%. DCPH stock has a five-year performance of %. Its 52-week range is between 39.42 and 68.4, which gives DCPH stock a 52-week price range ratio of 26.16%
Deciphera Pharmaceuticals Inc. currently has a PE ratio of -9.30, a price-to-book (PB) ratio of 4.71, a price-to-sale (PS) ratio of 60.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.37%, a ROC of -46.13% and a ROE of -46.81%. The company’s profit margin is -%, its EBITDA margin is -1 189.80%, and its revenue ttm is $42.03 Million , which makes it $0.73 revenue per share.
Of the last four earnings reports from Deciphera Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.09 for the next earnings report. Deciphera Pharmaceuticals Inc.’s next earnings report date is 04th May 2021.
The consensus rating of Wall Street analysts for Deciphera Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $73.71, which is +56.83% compared to the current price. The earnings rating for Deciphera Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Deciphera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Deciphera Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.65, ATR14 : 2.56, CCI20 : 121.82, Chaikin Money Flow : 0.13, MACD : -0.66, Money Flow Index : 59.48, ROC : 13.17, RSI : 49.88, STOCH (14,3) : 93.35, STOCH RSI : 0.96, UO : 61.19, Williams %R : -6.65), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Deciphera Pharmaceuticals Inc. in the last 12-months were: Daniel Flynn (Option Excercise at a value of $262 765), Daniel Flynn (Sold 508 shares of value $24 826 ), James Bristol (Option Excercise at a value of $219 192), James Bristol (Sold 92 323 shares of value $4 846 785 ), Matthew L. Sherman (Option Excercise at a value of $99 985), Matthew L. Sherman (Sold 132 shares of value $6 451 ), Michael Taylor (Option Excercise at a value of $1 083 157), Michael Taylor (Sold 573 099 shares of value $31 455 514 ), Patricia L. Allen (Option Excercise at a value of $617 520), Patricia L. Allen (Sold 24 000 shares of value $1 382 897 ), Steven L. Hoerter (Option Excercise at a value of $51 181), Thomas P. Kelly (Option Excercise at a value of $45 360), Thomas P. Kelly (Sold 24 524 shares of value $1 253 940 )
Deciphera Pharmaceuticals Inc.
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
CEO: Steven L. Hoerter
Telephone: +1 781 209-6400
Address: 200 Smith Street, Waltham 02451, MA, US
Number of employees: 350
